Gabapentin Market is Projected to Expand at a CAGR of 4.37% to reach USD 3,036.38 Million by 2032

𝐀𝐜𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭, 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐠𝐚𝐛𝐚𝐩𝐞𝐧𝐭𝐢𝐧 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟏,𝟗𝟖𝟏.𝟔𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐 𝐚𝐧𝐝 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟑,𝟎𝟑𝟔.𝟑𝟖 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟒.𝟑𝟕% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝.

Gabapentin is an anticonvulsant medication primarily used in the treatment of seizures and other neuropathic conditions. Along with controlling seizures and relieving nerve pain, gabapentin finds applications in the treatment of moderate-to-severe primary restless leg syndrome. It works by reducing the excitability of the brain's nervous cells, which are responsible for seizures and transmission of pain signals. Gabapentin is available in several forms, including tablets, oral solutions, and capsules. It's taken with or without food, as directed by the healthcare provider.

𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐡𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
https://www.polarismarketresearch.com/industry-analysis/gabapentin-market/request-for-sample

𝐓𝐨𝐩 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬

The gabapentin market is characterized by fragmentation. Several players are focusing on strategies such as mergers, acquisitions, and collaborations to garner a larger industry share. Some of the top players operating in the industry include:

• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd. Aurobindo Pharma Ltd.
• Lupin Limited
• Mylan N.V.
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Arbor Pharmaceuticals Inc.
• Zydus Cadila Healthcare Limited
• Glenmark Pharmaceuticals Ltd.
• Apotex Inc.
• Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd.
• Wockhardt Ltd

𝐊𝐞𝐲 𝐒𝐭𝐚𝐭𝐬

• The global gabapentin market was valued at USD 1,981.60 million in 2022.
• The industry is projected to grow at a compound annual growth rate of 4.37% during the forecast period from 2023 to 2032.
• The market is anticipated to reach USD 3,036.38 million by 2032.

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
https://www.polarismarketresearch.com/buy/2178/2

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬

The growing incidence of neuropathic pain and seizures is one of the key factors propelling the market forward. With the aging population, the prevalence of chronic pain and neurological conditions is expected to rise. This, in turn, is anticipated to fuel the demand for medications such as gabapentin.

The rising usage of gabapentin for off-label indications like insomnia, bipolar disorder, and anxiety is another factor propelling the industry forward. While the FDA hasn't specifically approved the drug for the treatment of these conditions, there is rising evidence that supports their effectiveness in treating these conditions.

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

• Gabapentin is highly prescribed and one of the top 30 prescription medications in the United States. The demand for gabapentin is projected to rise owing to the increased prevalence of chronic pain and neurological disorders.
• The Asia Pacific region is anticipated to witness a significant rise in the demand for gabapentin owing to the rising prevalence of various neurological disorders. Additionally, the increased healthcare spending is expected to drive the demand for medication in the region.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐬:
https://www.polarismarketresearch.com/industry-analysis/gabapentin-market

𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬:

𝐄𝐩𝐢𝐥𝐞𝐩𝐬𝐲:Gabapentin is primarily indicated for the treatment of epilepsy as an adjunctive therapy to control seizures in patients with partial seizures with or without secondary generalization.

𝐍𝐞𝐮𝐫𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐚𝐢𝐧:Gabapentin is widely used for the management of neuropathic pain associated with conditions such as diabetic neuropathy, postherpetic neuralgia, spinal cord injury, and trigeminal neuralgia.

𝐑𝐞𝐬𝐭𝐥𝐞𝐬𝐬 𝐋𝐞𝐠𝐬 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞:Gabapentin may be prescribed for the treatment of restless legs syndrome, a neurological disorder characterized by uncomfortable sensations in the legs and an irresistible urge to move them.

𝐎𝐟𝐟-𝐋𝐚𝐛𝐞𝐥 𝐔𝐬𝐞:Gabapentin is prescribed off-label for conditions such as fibromyalgia, anxiety disorders, migraine prophylaxis, and alcohol withdrawal syndrome, among others.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

𝐆𝐥𝐨𝐛𝐚𝐥 𝐆𝐚𝐛𝐚𝐩𝐞𝐧𝐭𝐢𝐧, 𝐃𝐨𝐬𝐚𝐠𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐔𝐒𝐃 𝐌𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟏𝟗-𝟐𝟎𝟑𝟐)
• Capsule
• Tablet

𝐆𝐥𝐨𝐛𝐚𝐥 𝐆𝐚𝐛𝐚𝐩𝐞𝐧𝐭𝐢𝐧, 𝐓𝐲𝐩𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐔𝐒𝐃 𝐌𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟏𝟗-𝟐𝟎𝟑𝟐)
• Branded
• Generic

𝐆𝐥𝐨𝐛𝐚𝐥 𝐆𝐚𝐛𝐚𝐩𝐞𝐧𝐭𝐢𝐧, 𝐌𝐞𝐭𝐡𝐨𝐝 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐔𝐒𝐃 𝐌𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟏𝟗-𝟐𝟎𝟑𝟐)
• Column-based
• Magnetic Beads
• Reagent-based
• Others

𝐆𝐥𝐨𝐛𝐚𝐥 𝐆𝐚𝐛𝐚𝐩𝐞𝐧𝐭𝐢𝐧, 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐔𝐒𝐃 𝐌𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟏𝟗-𝟐𝟎𝟑𝟐)
• Neuropathic Pain
• Epilepsy
• Restless Legs Syndrome
• Others

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

𝐄-𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/e-pharma-market

𝐄𝐫𝐞𝐜𝐭𝐢𝐥𝐞 𝐃𝐲𝐬𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/erectile-dysfunction-drugs-market

𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/global-autoimmune-disease-diagnostics-market

𝐏𝐫𝐮𝐫𝐢𝐭𝐮𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/global-pruritus-therapeutics-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

Polaris Market Research
Phone: +1-929-297-9727
Email: sales@polarismarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defence, among different ventures present globally.

This release was published on openPR.